Andreassen A K, Gullestad L, Bjørnerheim R, Forfang K, Kjekshus J
Medisinsk avdeling B, Rikshospitalet, Oslo.
Tidsskr Nor Laegeforen. 1995 Feb 28;115(6):725-8.
beta-adrenergic blockers have been considered relatively contraindicated in patients with peripheral arterial disease because of reports claiming that these drugs may worsen intermittent claudication. The authors review the published randomized controlled trials and discuss the results of comparisons of this treatment with treatment with alternative drugs. None of the studies of beta-blockade in patients with intermittent claudication showed a reduction of walking distance or impairment of peripheral flow compared with patients given placebo, except one study using a beta-blocker with intrinsic sympathomimetic activity. Alternative drugs are included in only few trials and do not seem to be beneficial. There is a lack of evidence to suggest that beta-blockers adversely effect walking capacity or worsen symptoms in mild to moderate intermittent claudication. beta-blockers should not be avoided if considered in other respects to be the optimal therapy for associated atherosclerotic disease.
由于有报道称β-肾上腺素能阻滞剂可能会加重间歇性跛行,所以在患有外周动脉疾病的患者中,这些药物被认为相对禁忌。作者回顾了已发表的随机对照试验,并讨论了这种治疗方法与使用其他药物治疗的比较结果。除了一项使用具有内在拟交感活性的β-阻滞剂的研究外,在间歇性跛行患者中进行的β-阻滞剂研究均未显示与给予安慰剂的患者相比,行走距离缩短或外周血流受损。其他药物仅在少数试验中使用,似乎并无益处。缺乏证据表明β-阻滞剂会对轻度至中度间歇性跛行患者的行走能力产生不利影响或使症状恶化。如果从其他方面考虑β-阻滞剂是相关动脉粥样硬化疾病的最佳治疗方法,那么不应避免使用。